Arcus Biosciences Enters into Collaborate with AstraZeneca to Trial Casdatifan and Volrustomig in Renal Cancer
Thursday, October 03, 2024
Arcus Biosciences has entered into a collaboration with AstraZeneca to investigate the potential of combining casdatifan (AB521), a HIF-2a inhibitor developed by Arcus, with volrustomig, AstraZeneca's PD-1/CTLA-4 bispecific antibody.
Casdatifan, currently in Phase 1/1b and Phase 1b/2 clinical trials, is a small-molecule inhibitor targeting HIF-2a, a transcription factor linked to the oxygen-sensing pathway disrupted in ccRCC.
Renal cell carcinoma is known to respond to treatments targeting CTLA-4, and initial studies of volrustomig in ccRCC have shown promising results.
The abnormal activity of HIF-2a due to genetic changes in the VHL pathway drives tumour growth and resistance to treatment. Casdatifan is still investigational and has not yet been approved for use by regulatory authorities.
This combination will be tested in patients with advanced clear cell renal cell carcinoma (ccRCC).
The aim of this partnership is to assess whether the combination of HIF-2a inhibition and volrustomig could lead to improved and longer-lasting outcomes for ccRCC patients.
AstraZeneca will manage the study to evaluate the safety and early effectiveness of this combination treatment.
This marks the second collaboration between the two companies, following their joint efforts in 2020 on a Phase 3 study of domvanalimab in combination with durvalumab for patients with non-small cell lung cancer.
Source: arcusbio.com
